Singapore-listed specialty pharmaceutical company iX Biopharma has opened its Entity’s flagship store on Tmall Global, Alibaba Group’s cross-border B2C e-commerce platform.

Metabolix4.20S$49 supplement which boosts levels of NAD+ in human body.Tmall provides Chinese consumers access to a large variety of international brands, and enables international retailers to sell directly to them without requiring an established presence in China.

Sharing its customer base with Taobao, Alibaba Group’s C2C e-commerce platform, Tmall has an extensive market reach of over 800 million mobile monthly active users as of December 2019.

Entity’s opening of its store on Tmall Global came a week after its maiden launch on JD Worldwide, another cross-border e-commerce platform based in China.

Stock price 

15 c

52-week range

13 – 29 c

Market cap

S$98 m

PE (ttm)

-

Dividend yield 

-

1-year return

-37%

Shares outstanding

649 m

Source: Bloomberg

Tmall and JD are the two largest ecommerce platforms in China, commanding over 85% of the total B2C e-commerce market in China.

With the successful launch of Entity on these platforms, consumers in China will now have access to the full range of Entity nutraceuticals.

They include leading products such as: 

RestoriX®, a nicotinamide supplement which boosts levels of NAD+ (nicotinamide adenine dinucleotide) to counter the process of ageing, while boosting energy levels and vitality; and

LumeniX®, a sublingual glutathione wafer that promotes skin fairness, while helping the body to build a stronger immunity against viral infections.

Target: Chinese consumers

EvanTan7.19

“Australian-made health supplements such as Entity are regarded by Chinese consumers as the gold standard of healthcare products due to Australia’s reputation for safety and quality. With the successful launch of our Entity flagship stores on Tmall Global and JD Worldwide, we have greatly improved the market reach and accessibility of our nutraceutical products to our target clientele in China. We believe that our established presence on these e-commerce platforms will allow us to penetrate the vast Chinese market and drive sustainable growth for the Group in the long-term.”


-- Eva Tan (photo),
Director of Corporate and Commercial Strategy of iX Biopharma

Entity nutraceuticals are developed and formulated by Australian scientists and manufactured in the Group’s TGA-approved, cGMP-compliant facility located in Victoria, Australia.

Entity nutraceuticals are sold in more than 250 pharmacies and health food shops in Sydney, Melbourne and Perth, Australia.

Entity nutraceuticals are natural, clinically-supported formulations.

Generic vitamin and mineral supplements that are widely available in the market serve to replenish nutritional deficiencies of a nonideal diet.

ix Biopharma said that Entity nutraceuticals, on the other hand, are designed to produce beneficial and perceptible improvement to a specific condition, and form an important part of a healthcare strategy to prevent more serious diseases.

Entity products are available in Singapore also via its website https://www.entity-health.com/about/

You may also be interested in:


You have no rights to post comments

Counter NameLastChange
AEM Holdings1.860-0.020
Best World2.480-
Boustead Singapore0.955-
Broadway Ind0.1400.006
China Aviation Oil (S)0.870-0.005
China Sunsine0.395-
ComfortDelGro1.400-0.010
Delfi Limited0.875-0.005
Food Empire1.130-
Fortress Minerals0.310-
Geo Energy Res0.295-
Hong Leong Finance2.430-
Hongkong Land (USD)3.4100.010
InnoTek0.5050.005
ISDN Holdings0.305-
ISOTeam0.047-0.001
IX Biopharma0.043-
KSH Holdings0.245-0.005
Leader Env0.049-
Ley Choon0.0560.004
Marco Polo Marine0.071-
Mermaid Maritime0.133-0.019
Nordic Group0.305-0.005
Oxley Holdings0.0890.002
REX International0.124-0.002
Riverstone0.925-0.005
Southern Alliance Mining0.480-
Straco Corp.0.490-
Sunpower Group0.230-0.005
The Trendlines0.063-0.001
Totm Technologies0.0210.001
Uni-Asia Group0.8450.015
Wilmar Intl3.160-0.020
Yangzijiang Shipbldg1.770-
 

We have 2576 guests and no members online

rss_2 NextInsight - Latest News